JPRN-jRCT2080221197未知1 期
Phase I Clinical Study of RG3502 in Combination With RG1273 in Patients With Advanced or Recurrent HER2-Positive Breast Cancer
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Inoperable advanced or recurrent breast cancer;
- •HER2-positive (FISH + or IHC 3+);
- •ECOG PS :0-2
排除标准
- •Clinically significant cardiac disease;
- •Grade 3 or higher Hypersensitivity for trastuzumab
研究者
相似试验
未知
2 期
Phase II clinical study of RG3502 in HER2 positive breast cancer patientsJPRN-jRCT2080221240Chugai Pharmaceutical Co., Ltd.70
招募中
不适用
A Phase I/II Study of Combination Therapy of CG200745 PPA (Histone Deacetylase Inhibitor) with Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic CancerNeoplasmsKCT0002037CrystalGenomics48
未知
1 期
Phase I Clinical Study of RG7304 in Patients with Advanced Solid TumorsJPRN-jRCT2080221452Chugai Pharmaceutical Co., Ltd.30
已完成
2 期
A phase II/III clinical study of R442(Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-UMIN000000692CHUGAI PHARMACEUTICAL CO.LTD.260
未知
3 期
A phase II/III clinical study of R442 (Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-jRCT2080220384Chugai Pharmaceutical Co., Ltd.